We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series.
- Authors
Moreno-Alonso, Deborah; Llorens-Torromé, Sílvia; Corcoy de Febrer, Blanca; Amandi García, María; Serrano-Bermúdez, Gala; Trelis-Navarro, Jordi; Mayoral-Rojals, Victor; Serrano-Afonso, Ancor
- Abstract
Background: Capsaicin is a highly selective agonist of the transient receptor potential vanilloid 1. The adhesive capsaicin patch provides a high capsaicin concentration (8%) directly in the painful area – its efficacy in benign peripheral neuropathic pain (diabetic neuropathy or postherpetic neuralgia) has recently been described in the literature. However, there is scant evidence of its efficacy in chemotherapy-induced peripheral neuropathy (CIPN). This is a concern for patients with multiple myeloma, who suffer from peripheral neuropathic pain induced by first-line treatments (bortezomib or thalidomide). Aim: To describe improved control of CIPN in patients with multiple myeloma using adhesive capsaicin 8% patch. Methods: We opted for a retrospective observational case series. Between October 2017 and October 2020, we collected clinical data from adult multiple myeloma patients affected by CIPN who were administered the capsaicin 8% patch in our palliative care outpatient clinic. We compiled Numerical Pain Rating Scale (NPRS) scores, patients' medication needs and performance status before and after patch application. Results: Two women and five men with an average age of 62.85 years received bortezomib. Two patients (28.57% of the sample) also received thalidomide. The average NPRS score before patch application was 6.42/10. Five of the seven patients (71.42%) received a mean daily oral morphine dose of 52.85 mg/day, five (71.42%) received gabapentinoids and one (14.28%) received antidepressants. The average NPRS score decreased to 4/10 seven days after patch application, while the mean daily oral morphine dose remained stable. Performance status improved slightly in two patients (28.57%) and remained stable in the rest. One patient (14.28%) required an extra analgesic dose during patch application. Conclusions: Capsaicin 8% patch application appears to reduce pain intensity in patients with multiple myeloma suffering from CIPN.
- Subjects
NEURALGIA; MULTIPLE myeloma; PAIN measurement; PALLIATIVE treatment; OUTPATIENT services in hospitals; MORPHINE; THALIDOMIDE; CANCER patients; RETROSPECTIVE studies; DESCRIPTIVE statistics; ORAL drug administration; FUNCTIONAL status; CANCER chemotherapy; BORTEZOMIB; ANTIDEPRESSANTS; MEDICAL records; ACQUISITION of data; GABAPENTIN; CAPSAICIN; TRANSDERMAL medication; CASE studies; NEEDS assessment; PATIENT aftercare
- Publication
Journal of Oncology Pharmacy Practice, 2024, Vol 30, Issue 4, p752
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/10781552241230887